glp-1 long term use long-term safety The Trap: Your Jumpstart Might Be a Forever Commitment Your GLP-1 journey is unique, – Those discontinuing GLP-1 medications rapidly

The EMPA-KIDNEY trial enrolled a larger proportion of participants without diabetes mellitus and included individuals with lower mean eGFR (37.3 mL/min/1.73 m) and median UACR (329 mg/g) compared to DAPA-CKD

104,112 Accumulated evidence suggests that both glucagon like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors may affect renal function in both glucose lowering dependent and independent mechanisms of action

Its essential you partner with a PBM that can evolve from a simple processor to a true partner focused on net cost and clinical quality

They stimulate insulin secretion from pancreatic beta cells in a glucose-dependent manner, meaning insulin is only released when blood glucose levels are elevated

That conversation above